Impact and persistence of cirrhotic cardiomyopathy after liver transplantation

Area of Science:

• Cardiology
• Hepatology
• Transplantation Science

Background:

• Cirrhotic cardiomyopathy presents with systolic/diastolic dysfunction and conduction abnormalities.
• Liver transplantation is a potential treatment for end-stage liver disease.
• Predictors of post-transplant outcomes require further investigation.

Purpose of the Study:

• To assess if pre-transplant diastolic dysfunction (DD) and prolonged corrected QT (QTc) predict mortality, graft failure, or major cardiovascular events post-liver transplant.
• To evaluate the reversibility of cirrhotic cardiomyopathy after liver transplantation.

Main Methods:

• Retrospective analysis of 243 adult liver transplant recipients (2007-2009).
• Data collection included institutional registry, medical records, and echocardiography.
• Primary composite outcome: mortality, graft failure, and major cardiovascular events.
• Follow-up averaged 5.2 years.

Main Results:

• 113 patients had Grade 1 DD, 16 had Grade 2 DD.
• Mean pre-transplant QTc was 453 ms.
• 75 patients (31%) met the composite outcome.
• Diastolic dysfunction did not significantly predict the composite outcome (P=.17).
• Prolonged QTc was independently associated with the composite outcome (HR: 1.01, P=.05).
• Diastolic dysfunction and left ventricular mass index worsened post-transplant (P<.001, P=.001).

Conclusions:

• QTc prolongation is linked to poorer outcomes after liver transplantation.
• Diastolic dysfunction did not predict adverse events but significantly worsened post-transplant.
• Cirrhotic cardiomyopathy parameters may change after liver transplantation, impacting patient management.